Abstract
Evidence that the secretion of growth hormone (GH) is under the dual control of a hypothalamic stimulating hormone — growth hormone releasing hormone (GHRH) — and an inhibitory factor was already presented by Krulich et al. in 1968. However, only in 1973 did Brazeau et al. isolate a tetradecapeptide from ovine hypothalami that inhibited GH or somatotropin secretion. The peptide was called somatostatin or growth-hormone release-inhibiting hormone.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ (1988) Treatment of acromegaly with the long-acting Somatostatin analog SMS 201–995. J Clin Endocrinol Metab 66: 16–23
Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P et al (1982) SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31: 133–140
Beckers A, Abs R, Mahler C, Vandalem JL, Pirens G, Hennen G, Stevenaert A (1991) Thyrotropin secreting pituitary adenomas: Report of seven cases. J Clin Endocrinol Metab 72: 477–483
Beck-Peccoz P, Mariotti S, Guillauseau PJ, Medri G, Piscitelli G, Bertoli A, Barbarino A, Rondena M, Chanson Ph, Pinchera A, Faglia G (1989) Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analogue SMS 201–995. J Clin Endocrinol Metab 68: 208–214
Bertagna X, Favrod-Coune C, Escourolle H et al (1989) Suppression of ectopic adrenocorticotropin secretion by the long-acting somatostatin analogue octreotide. J Clin Endocrinol Metab 68: 988–991
Besser GM (1992) In: Liuzzi A, Sobrinho LG, Besser GM (eds) Proceedings of the Workshop “Practical Approaches to the Diagnosis and Treatment of Acromegaly”. Metabolism 41 [Suppl 2]: 87–90
Besser GM, Wass JAH (1987) The use of dopamine agonists in the management of acromegaly. In: Robbins RJ, Melmed S (eds) Acromegaly. Plenum, New York, pp 261266
Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumour shrinkage. Endocr Rev 13: 220–240
Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179: 77–79
Buscail L, Tauber JP, Puet-Bosquet L et al (1989) Gallstones and treatment with octreotide for acromegaly. BMJ 299: 1162
Chan AW, MacFarlane IA, van Heyningen C et al (1990) Clinical hyperthyroidism due to non-neoplastic inappropriate thyrotropin secretion. Postgrad J Med 66: 743–746
Chanson P, Warnet A (1992) Treatment of thyroid-stimulating hormone-secreting adenomas with octreotide. Metabolism 41 [Suppl 21: 62–65
Chiodini PG, Attanasio R, Orlandi P, Cozzi R (1991) Growth hormone release inhibiting hormone. In: Motta M (ed) Brain endocrinology, 2nd edn. Raven, New York, pp 301–313
Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petrocini M, Liuzzi A, del Pozo E (1987) Medical treatment of acromegaly with SMS 201–995, a somatostatin analogue: a comparison with bromocriptine. J Clin Endocrinol Metab 64: 447–453
Ching LJC, Sandler LM, Kraenzlin ME, Burrin JM, Joplin GF, Bloom SR (1985) Long term treatment of acromegaly with a long-acting analogue of somatostatin. BMJ 290: 284–287
Christensen SE, Weeke J, Orskov H, Moller N, Flyvbjerg A, Harris AG, Lund E, Jorgensen J (1987) Continuous subcutaneous pump infusions of somatostatin analogue 201–995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol 27: 297–306
Chrubasik J, Meynadier J, Blond S et al. (1984) Somatostatin: a potent analgesic. Lancet 2:1208–1209
Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD (1987) Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med 317: 12–17
Dowling RH, Hussaini SH, Murphy GM, Besser GM, Wass JAH (1992) Gallstones during octreotide therapy. Metabolism 41 [Suppl 2]: 22–33
Ezzat S, Ren S-G, Braunstein GD, Melmed S (1992) Octreotide stimulates Insulin-like growth factor binding protein-1: a potential pituitary independent mechanism for drug action. J Clin Endocrinol Metab 75: 1459–1463
Faglia G, Bazzoni N, Spada A, Arosio M, Ambrosi B, Spinelli F, Sara R, Bonino C, Lunghi F (1991) In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analogue of somatostatin (123SDZ 204090). J Clin Endocrinol Metab 73: 580–856
Guillausseau PJ, Chanson P, Timsit J et al (1987) Visual improvement with SMS 201–995 in a patient with a thyrotropin-secreting adenoma. N Engl J Med 317: 53–54
Halse J, Harris AG, Kvistborg A, Kjartansson O, Smiseth O, Djosland O, Hass G, Jervell J (1990) A randomized study of SMS 201–995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects. J Clin Endocrinol Metab 70: 1254–1261
Harris A (1991) Acromegaly. Sandoz, Basel Harris AG, Prestele H, Herold K, Boerlin V (1988) Long-term efficacy of Sandostatin (SMS 201–995, octreotide) in 178 acromegalic patients: results from the international multicen-42 K. von Werder ter acromegaly study group. In: Lamberts SWJ (eds) Sandostatin in the treatment of acromegaly. Springer, Berlin, Heidelberg New York, pp 117–125
Heron L, Thomas F, Ruiz JM, Henan S, Schatz B, Kuhn JM (1992) Treatment of acromegaly with a longacting formulation of the somatostatin analogue laureotide. One year follow up. Abstract 714, Endocrine Society San Antonio, Texas
Holland LJ, van Koetsveld PM, van Vroonhoven CCJ, Stefanko SZ, Lamberts SWJ (1989) Heterogeneity of growth hormone (GH) release by individual pituitary adenoma cells from acromegalic patients, as determined by the reverse hemolytic plaque assay: effects of SMS 201–995, GH-releasing hormone and thyrotropin releasing hormone. J Clin Endocrinol Metab 68: 613–620
Horn K, Erhardt F, Fahlbusch R, Pickardt CR, von Werder K, Scriba PC (1976) Recurrent thyrotoxic goiter and galactorrhea-amenorrhea syndrome due to an autonomous thyrotropin and prolactin producing pituitary adenoma. J Clin Endocrinol 43: 142
James R, Chatterjee S, White MC, Hall K, Moller N, Kendall-Taylor P (1989) Continuous infusion of octreotide in acromegaly. Lancet 2: 1083–1087
Krulich I, Dhariwal APS, McCann SM (1968) Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83: 783–790
Lamberts SWJ, Bakker WM, Reubi JC (1990) The value of somatostatin receptor imaging in the localization of endocrine and brain tumours. N Engl J Med 323: 1246–1249
Lamberts SWJ, Uitterlinden P, Verschoor L, van Dorgen KJ, del Pozo E (1985) Longterm treatment of acromegaly with the somatostatin analogue SMS 201–995. N Engl J Med 313: 1576–1580
Lamberts SWJ, Zweens M, Klijn JGM, van Vroohoven CCJ, Stefanko SZ, del Pozo E (1986) The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201–995 in patients with prolactinomas and acromegaly. Clin Endocrinol 25:201–212
Lamberts SWJ, Uitterlinden P, del Pozo E (1987) SMS 201–995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab 65: 703–710
Lamberts SWJ, Uitterlinden P, Schujff PC, Klijn JGM (1988) Therapy of acromegaly with Sandostatin: the predictive value of an acute test, the value of serum somatomedin C measurements in dose adjustment and the definition of a biochemical `cure’. Clin Endocrinol (0x0 289: 411–420
Lamberts SWJ, Uitterlinden P, Klijn JMG (1989) The effect of the longacting somatostatin analogue SMS 201–995 on ACTH secretion in Nelson’s Syndrome and Cushing’s Syndrome. Acta Endocrinol 120:760–766
Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Müller EE, Silvestrini F (1974) Decrease of plasma growth hormone (GH) levels in acromegalics following CB 1542 Br alpha-ergocryptine) administration. J Clin Endocrinol Metab 38: 910–912
Liuzzi A, Dallabonzana D, Oppizzi G, Cozzi R, Strada S, Arrigoni GL, Chiodini PG (1991) Is there a real medical treatment for the “non-secreting” pituitary adenomas? In: Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A (eds) Pituitary adenomas: new trends in basic and clinical research. ICS 961, Elsevier, Amsterdam, pp 383–390
Losa M, Oeckler B, Schopohl J, Müller OA, Alba-Lopez J, von Werder K (1989) Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedinC measurement in acromegaly. J Neurosurg 70: 561–567
Lorcy Y, Delambre C, Leguerrier AM et al (1989) Traitement de la maladie de Cushing par un analogue de la somatostatine (SMS 201–995): Quatres observations. Ann Endocrinol 50: 311 (Abstr 106)
Mehltretter G, Heinz S, Schopohl J, von Werder K, Müller OA (1991) Long-term treatment with SMS 201–995 in resistant acromegaly: effectiveness of high doses and continuous subcutaneous infusion. Klin Wochenschr 69: 83–90
Müller OA, von Werder K (1992) Ectopic production of ACTH and corticotropin-releasing hormone (CRH). J Steroid Biochem Mol Biol 43: No. 5, 403–408
Muhr C, Bergström M, Lundberg PO, Bergström K, Langström B (1988) Positron emission tomography for the in vivo characterization and follow-up of treatment in pituitary adenomas. Adv Biosci 69: 163–170
Petrini L, Pilosu R, Marcello A, Mastio F, Bartolomei MP, Nardi M, Martino E (1990) Effect of octreotide (SMS 201–995) administration on the size of nonfunctional pituitary tumours. J Endocrinol Invest 13 [Suppl 1] :161
Pieters GFFM, Van Liessum PA, Smals AGH et al (1987) Longterm treatment of acromegaly with Sandostatin (SMS 201–995). Normalization of most anomalous growth hormone responses. Acta Endocrinol [Suppl] 18: 9–18
Plöckinger V, Dienemann D, Quabbe H-J (19990) Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab 71:1658–1662
Quabbe Hi (1982) Treatment of acromegaly by transsphenoidal operation, 90-yttrium implantation and bromocriptine: results in 230 patients. Clin Endocrinol (Oxf) 16: 107–119
Quabbe HJ, Plöckinger U (1989) Dose-response study and long-term effect of the somatostatin analogue octreotide in patients with therapy-resistant acromegaly. J Clin Endocrinol Metab 68: 873–881
Reichlin S (1983) Somatostatin. N Engl J Med 309:1495–1501, 1536–1563
Renard E, Barjon JN, Bringer J, Frèrebeau P, Jaffiol C (1990) Quick improvement of visual field complications due to extensive nonfunctioning hypothalamic or pituitary tumours with a somatostatin analogue (SMS 201–995). J Endocrinol Invest 13 [Suppl 2]: 74
Reschini E, Giustina G, Cantalamessa L, Peracchi M (1976) Hyperthyroidism with elevated plasma TSH levels and pituitary tumor: Study with somatostatin. J Clin Endocrinol Metab 43: 924–927
Reubi JC, Landolt AM (1989) The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 68:844–850
Reubi JC, Heitz PU, Landolt AM (1987) Visualization of somatostatin receptors and corre-lation with immunoreactive growth hormone and prolactin in human pituitary ade-nomas: evidence for different tumor subclasses. J Clin Endocrinol Metab 65: 65–73
Ross DA, Wilson CB (1988) Results of transsphenoidal microsurgery for growth hormone secreting pituitary adenomas in a series of 214 patients. J Neurosurg 68: 854–867
Sano T, Ma SL, Kovacs K (1991) Growth hormone releasing hormone producing tumours: clinical, biochemical and morphological manifestations. Endocr Rev 9: 357–373
Sassolas G (1992) The role of sandostatins in acromegaly. Metabolism 41 [Suppl 2]: 39–43
Sassolas G, Melmed S (1992) Symposium: basic somatostatin research. Metabolism 41 [Suppl 2]: 11–16
Sassolas G, Serusclat P, Claustrat B, Trouillas J, Merabt S, Cohen R, Souquet JC (1988) Plasma alpha-subunit levels during the treatment of pituitary adenomas with the somatostatin analogue SMS 201–995. Horm Res 29: 124–128
Sassolas G, Harris AG, James-Deidier A (1990) Long term effect of incremental doses of the Somatostatin analogue SMS 201–995 in 58 acromegalic patients. J Clin Endocrinol Metab 71: 391–397
Schopohl J, Wiedemann Y, Nass R, Strasburger A, Moyto J, Garzon F, Thomas F (1993) Treatment of resistant acromegaly: high dose octreotide therapy versus a slow release formulation of the somatostatin analogue lanreotide. Exper Clin Endocr (in press)
Siler TM, Yen SSC, Vale W, Guillemin R (1974) Inhibition by somatostatin of the release of TSH induced in man by thyrotropin-releasing factor. J Clin Endocrinol Metab 38: 742–746
Stalla GK, Stalla J, Mojito J, Höllt V, Oeckler R, Buchfelder M, Müller OA (1989) Regula-tion of corticotroph adenoma cells in vitro. Acta Endocrinol 190 [Suppl 1]: 209
Stevenaert A, Harris AG, Kovacs K, Beckers A (1992) Presurgical octreotide treatment in acromegaly. Metabolism 41 [Suppl 2]: 51–58
Vance ML, Harris AG (1991) Longterm treatment of 189 acromegalic patients with the somatostatin analogue octreotide. Arch Intern Med 151: 1573–1578
Vos P, Croughs RJM, Thijssen JHH, van’t Verlaat JW, van Ginkel LA (1988) Response of luteinizing hormone-secreting pituitary adenomas to a long-acting somatostatin analogue. Acta Endocrinol 118: 587–590
Warnet A (1990) Effect of Sandostatin on optic chiasm compression due to non GH-, non TSH-secreting pituitary adenomas. J Endocrinol Invest 13 [Suppl 2]: 74
Warnet A (1992) The Role of octreotide (Sandostatin) in Non-Growth Hormone-, Non-Thyroid-Stimulating Hormone-, and Non-Prolactin-Secreting Adenomas. Metabolism 41 [Suppl ]21:59–61
Weintraub BD, Gershengorn MC, Kourides IA, Fein H (1981) Inappropriate secretion of thyroid-stimulating hormone. Ann Intern Med 95: 339–351
von Werder K (1975) Wachstumshormon-und Prolaktin-Sekretion des Menschen. Urban and Schwarzenberg, Munich
von Werder K, Faglia G (1992) Potential indications for octreotide in endocrinology. Metabolism 41 [Suppl 2]: 91–98
von Werder K, Fahlbusch R, Losa M, Oeckler R, Pichl J, Schopohl J (1987) Decision analysis of treatment options in acromegaly. In: Robbins RJ, Melmed S (eds) Acromegaly. Plenum, New York, pp 267–280
von Werder K, Schopohl J, Wolfram G, Mojto J, Stalla GK, Losa M, Müller OA (1988) Ectopic production of pituitary hormones and releasing hormones. Adv Biosci 69: 87–95
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
von Werder, K. (1993). Somatostatin Analogues in Pituitary Adenomas. In: Höffken, K. (eds) Peptides in Oncology II. Recent Results in Cancer Research, vol 129. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84956-5_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-84956-5_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-84958-9
Online ISBN: 978-3-642-84956-5
eBook Packages: Springer Book Archive